Patient: Sabrina Mesiemore (45F) | DOB: 05/23/1980
Visit Date: March 9, 2026 | Review Date: March 19, 2026
From: Psychiatric MD Collaborator | To: Stacy Pascarella, APRN
Collaborative Agreement: Psychiatry MD-APRN Practice
The clinical decision-making demonstrates sound diagnostic reasoning, appropriate patient-centered care planning, and evidence-based treatment selection. The current course is reasonable and approvable with specific recommendations to optimize outcomes and mitigate risks.
| Diagnosis | Code | Status | Recommendation |
|---|---|---|---|
| PTSD, Chronic Severe | F43.10 | ✅ Appropriate | Maintain; consider specifying "with dissociative symptoms" if derealization/depersonalization present during flashbacks |
| Prolonged Grief Disorder | F43.81 | ✅ Appropriate | Maintain; distinct from normative grief and MDD |
| Bipolar Disorder, Depressed | F31.4 | ✅ Appropriate | Maintain; mood stability confirmed |
| Panic Disorder | F41.0 | ⚠️ Modify | Remove active status — no current symptoms; specify "in remission" or remove |
| Other Specified Anxiety Disorder | F41.8 | ✅ Appropriate | Maintain as residual category |
| Additional consideration: Nightmare Disorder (F51.5) — specify separately given severity, treatment resistance, and distinct therapeutic target | |||
| Medication | Assessment | Recommendation |
|---|---|---|
| Fluvoxamine (continuation) | Reasonable | Continue; appropriate for intrusive symptoms and OCD features |
| Vraylar (cariprazine) (continuation) | Reasonable | Continue; monitor metabolic parameters per guidelines |
| Lamictal (lamotrigine) taper | ⚠️ Requires modification | Suspend taper until trauma-focused therapy completed; mood destabilization risk during EMDR is significant |
| Nightmare pharmacology | Gap identified | Initiate trial prior to EMDR: prazosin rechallenge 1mg OR gabapentin 300-600mg OR topiramate 25-50mg |
BMI 33.94 on cariprazine requires fasting glucose, HbA1c, lipids per atypical antipsychotic guidelines
| Intervention | Assessment | Recommendation |
|---|---|---|
| Supportive/humanistic therapy | Reasonable | Continue; strong therapeutic alliance evident |
| EMDR referral | Reasonable with conditions | Approved pending: (1) sleep stabilization, (2) mood stability 8+ weeks, (3) provider bipolar experience confirmed |
| Self-compassion letter | Excellent | Well-constructed; maintain |
| Behavioral activation (pool) | Excellent | Leverages spontaneous positive behavior; encourage continuation |
16-session protocol with stronger evidence base for prolonged grief disorder than EMDR alone; may sequence before or concurrent with EMDR
| Timeline | Action | Responsible |
|---|---|---|
| 2 weeks | Review sleep study; initiate nightmare pharmacology | APRN/PCP |
| 4 weeks | Confirm mood stability for EMDR clearance; metabolic labs | APRN/MD |
| 6 weeks | Reassess sleep and nightmare severity | APRN |
| 8 weeks | EMDR initiation if parameters met | EMDR Provider |
| Ongoing | Weekly supportive therapy; biweekly psychiatric check-ins during EMDR | APRN/MD |
Recommendations: Implement enhancements above to optimize safety and efficacy
Prognosis: Favorable given strong therapeutic engagement, insight, and spontaneous behavioral activation